BNGO Stock Forecast: BioNano Genomics Inc boosted by DNA study

  • NASDAQ: BNGO has soared by 14% on Tuesday to $12.16.
  • BioNano Genomics announced publication of a study on DNA methylation.
  • BNGO is one of the best performing stocks of 2021.

Update: BNGO shares are trading higher on Tuesday as the company announced that its "Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research". 


Going from strength to strength – BioNano Genomics (NASDAQ: BNGO) has surged by 28.73% on Monday, closing at $12.58. While shares are off the fresh 52-week highs of $13.65 and may continue correcting on Tuesday, the surge is an incredible feat for the firm. San Diego-based Bioano hit a 52-week low of $0.25 late last year, making its leap even more impressive.

The genetics company impressed the medical community and investors with its recent breakthroughs including mapping genes related to the autism spectrum, cancer, and even COVID-19. Its work allows for better care and may also translate into higher sales down the road. 

Investors were impressed enough to provide the company with $230 million in its underwritten offering of common stock. The financial exercise includes options to buy more stocks at a discounted price. The prospects of offering new stock had already weighed on BNGO earlier in the year, and closing the round was shrugged off on Monday. 

Raising money became easier when professional investors also gave BioNano Genomics some backing. Jason McCarthy, an analyst with Maxim, bumped up his price forecast from $2 to $14. At the current closing price, there is still room for the company to run. McCarthy was impressed by the firm's Next-Generation Cytogenomics Symposium – an event where it showcased its Saphyr optical genome mapping (OGM)  capabilities. 

BNGO stock price

NASDAQ: BNGO has already dropped from the highs and may continue lower. However, such a correction makes sense after the meteoric rise. To the downside, the levels to watch are the round $12 level and then Monday's low of $10.45. 

Looking up, Monday's close at $12.58 is followed by $13 and then by $13.65, the 52-week high. McCarthy's price forecast of $14 is next in line. 

Best Stocks to Buy Forecast 2021: Vaccines and zero rates to broaden recovery

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

Are you new to trading or have been trading for a while and you feel stuck?

Try with us!
Become Premium!

Latest Forex News

Latest Forex News

Editors’ Picks

EUR/USD holds above 1.22 as the dollar slides across the board

EUR/USD has extended its gains and has topped 1.22, the highest since February. The safe-haven dollar is weakening amid the risk-on mood and as the Fed sticks to its dovish policy. US housing figures were mixed. The Fed's Bostic is set to speak later. 


GBP/USD extends corrective slide below 1.4200

GBP/USD trades around 1.4180, retreating from 1.4219, the highest since February. Britain's unemployment rate surprisingly dropped to 4.8% as the reopening continues. The dollar is on the back foot amid the upbeat market mood.


XAU/USD consolidates below $1870 amid risk-on mood

Gold price has entered a phase of upside consolidation, having faced rejection once again above $1870. The gold price looks unimpressed by the latest leg down in the US dollar, amid dovish Fed expectations.

Gold News

SEC attempts to block XRP holders from presenting evidence in Ripple case

The Securities & Exchange Commission filed another objection to the motion to intervene by XRP holders. The government agency argues that allowing third-party defendants into the case would “sow chaos” into the litigation.

Read more

Coinbase reveals intention to raise $1.25 billion following direct listing

Since its debut on the Nasdaq, Coinbase’s share price has merely collapsed. Given the recent weakness in its stock price, the leading cryptocurrency exchange is looking for a further cash injection. 

Read more